| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/JMBI.2001.4574 |
| P698 | PubMed publication ID | 11292349 |
| P50 | author | Anthony A Holder | Q46474398 |
| Evelina Angov | Q107291505 | ||
| P2093 | author name string | J Feeney | |
| C Uthaipibull | |||
| I T Ling | |||
| J A Guevara Patiño | |||
| S E Syed | |||
| B Hansen | |||
| B Aufiero | |||
| B Birdsall | |||
| C Ockenhouse | |||
| J A Lyon | |||
| K Fegeding | |||
| W D Morgan | |||
| P2860 | cites work | RASMOL: biomolecular graphics for all | Q29547757 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| antibody | Q79460 | ||
| Plasmodium falciparum | Q311383 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1381-1394 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Journal of Molecular Biology | Q925779 |
| P1476 | title | Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum | |
| P478 | volume | 307 |
| Q37264673 | A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies |
| Q36063959 | A new release on life: emerging concepts in proteolysis and parasite invasion |
| Q37529646 | A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila. |
| Q36368933 | A robust neutralization test for Plasmodium falciparum malaria |
| Q34594028 | Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria |
| Q39689576 | An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults n |
| Q34334187 | Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum |
| Q33761687 | Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion |
| Q42695755 | Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum |
| Q34534163 | Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda |
| Q33223740 | Binding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1 |
| Q78625792 | C-terminal processing of the toxoplasma protein MIC2 is essential for invasion into host cells |
| Q37448753 | Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection |
| Q37522507 | Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. |
| Q35908746 | Cloning and Sequence Analysis of Recombinant Plasmodium vivax Merozoite Surface Protein 1 (PvMSP-142 kDa) In pTZ57R/T Vector |
| Q36862490 | Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children |
| Q36898029 | Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum |
| Q27641117 | Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate |
| Q28087077 | Current efforts and future prospects in the development of live mycobacteria as vaccines |
| Q44438134 | Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine |
| Q35902659 | Epidemiological factors that promote the development of severe malaria anaemia in children in Ibadan |
| Q33905364 | Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum |
| Q34546246 | Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil |
| Q37582419 | Fc-receptors and immunity to malaria: from models to vaccines. |
| Q34249359 | Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection |
| Q36576319 | Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia |
| Q34171724 | High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria |
| Q30409373 | Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice |
| Q54478086 | Hydrophobic moeties in recombinant proteins are crucial to generate efficient saponin-based vaccine against Apicomplexan Babesia divergens. |
| Q44151361 | Identification of antigenically active tryptic fragments of apical membrane antigen-1 (AMA1) of Plasmodium chabaudi malaria: strategies for assembly of immunologically active peptides |
| Q21032484 | Immune mechanisms in malaria: new insights in vaccine development |
| Q47989426 | Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies |
| Q34842236 | Immunity to asexual blood stage malaria and vaccine approaches |
| Q47964774 | Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-119) antigen of Plasmodium falciparum |
| Q48021487 | Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants |
| Q34601683 | Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children |
| Q30967137 | Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1 |
| Q37451160 | Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin G1 (IgG1) and IgG3 antibodies. |
| Q43815491 | Inhibition of glycosyl-phosphatidylinositol biosynthesis in Plasmodium falciparum by C-2 substituted mannose analogues |
| Q63045331 | Inhibition of parasite invasion by monoclonal antibody against epidermal growth factor-like domain of Plasmodium vivax merozoite surface protein 1 paralog |
| Q34109788 | Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodies |
| Q42151010 | MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum |
| Q47896646 | Malaria invades Yorkshire |
| Q36313955 | Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1 |
| Q43013555 | Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys |
| Q26772878 | Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria |
| Q81185616 | Modification of a human monoclonal antibody Fab fragment specific for Plasmodium falciparum 19-kDa C-terminal merozoite surface protein 1 by site-directed mutagenesis |
| Q36302325 | Opinion: antibody-based therapies for malaria |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q36666596 | Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes |
| Q35805390 | Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development |
| Q35944117 | Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria |
| Q33613937 | Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response |
| Q35762375 | Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies |
| Q41844553 | Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses |
| Q33282524 | Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum |
| Q33356029 | Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses |
| Q28345224 | Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region |
| Q31050217 | Proteomic analysis of cleavage events reveals a dynamic two-step mechanism for proteolysis of a key parasite adhesive complex |
| Q34855814 | Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria |
| Q33772752 | Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria |
| Q44588579 | Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum |
| Q37762275 | Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. |
| Q48036618 | Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. |
| Q37559892 | The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. |
| Q33558061 | The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites |
| Q37523653 | The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia |
| Q37471465 | The future for blood-stage vaccines against malaria |
| Q34131183 | The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies |
| Q33285037 | The importance of human FcgammaRI in mediating protection to malaria |
| Q27681234 | The structure of Plasmodium yoelii merozoite surface protein 119, antibody specificity and implications for malaria vaccine design |
| Q34206438 | Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodies |
| Q34572160 | Towards a blood-stage vaccine for malaria: are we following all the leads? |
| Q44406575 | Toxicity of the staphylococcal enterotoxin B mutants with histidine-to-tyrosine substitutions. |
| Q38598055 | Workshop report: Malaria vaccine development in Europe--preparing for the future. |
Search more.